Clinical Implications of Discordant Early Molecular Responses in CML Patients Treated with Imatinib

A reduction in BCR-ABL1/ABL1(IS) transcript levels to <10% after 3 months or <1% after 6 months of tyrosine kinase inhibitor therapy are associated with superior clinical outcomes in chronic myeloid leukemia (CML) patients. In this study, we investigated the reliability of multiple BCR-ABL1 th...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Int J Mol Sci
Main Authors: Stella, Stefania, Zammit, Valentina, Vitale, Silvia Rita, Pennisi, Maria Stella, Massimino, Michele, Tirrò, Elena, Forte, Stefano, Spitaleri, Antonio, Antolino, Agostino, Siragusa, Sergio, Accurso, Vincenzo, Mannina, Donato, Impera, Stefana, Musolino, Caterina, Russo, Sabina, Malato, Alessandra, Mineo, Giuseppe, Musso, Maurizio, Porretto, Ferdinando, Martino, Bruno, Di Raimondo, Francesco, Manzella, Livia, Vigneri, Paolo, Stagno, Fabio
Format: Artigo
Jezik:Inglês
Izdano: MDPI 2019
Teme:
Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC6539817/
https://ncbi.nlm.nih.gov/pubmed/31064152
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/ijms20092226
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki